

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 March 2025 (20.03.2025)



(10) International Publication Number
WO 2025/059511 A1

(51) International Patent Classification:

A61K 31/7125 (2006.01) C12N 15/113 (2010.01)
A61P 25/08 (2006.01)

(21) International Application Number:

PCT/US2024/046682

(22) International Filing Date:

13 September 2024 (13.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/538,713	15 September 2023 (15.09.2023)	US
63/542,017	02 October 2023 (02.10.2023)	US
63/604,103	29 November 2023 (29.11.2023)	US
63/651,681	24 May 2024 (24.05.2024)	US
63/672,118	16 July 2024 (16.07.2024)	US
63/686,359	23 August 2024 (23.08.2024)	US
63/689,297	30 August 2024 (30.08.2024)	US

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **PRAXIS PRECISION MEDICINES, INC.**
[US/US]; 99 High Street, 30th Floor, Boston, MA 02110 (US).

(72) Inventors: **MOTEL, William**; C/o Praxis Precision Medicines, Inc, 99 High Street, 30th Floor, Boston, MA 02110 (US). **WYANT, Alyssa**; C/o Praxis Precision Medicines, Inc., 99 High Street, 30th Floor, Boston, MA 02110 (US). **HARD, Marjie**; C/o Praxis Precision Medicines, Inc., 99 High Street, 30th Floor, Boston, MA 02110 (US).

(74) Agent: **MARGOLIN, Yelena** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: ELSUNERSEN / PRAX-222 FOR USE IN THE TREATMENT OF SCN2A-RELATED DISORDERS

(57) Abstract: Provided are methods of treating a subject with a SCN2A-related disorder, e.g., Developmental and Epileptic Encephalopathies (DEE), comprising administering to the subject an oligomeric compound. Also provided are methods of reducing frequency of seizures experienced by a subject with a SCN2A-related disorder, comprising administering to the subject an oligomeric compound.

WO 2025/059511 A1